CHICAGO--(BUSINESS WIRE)--Antares today announced a record year for the firm closing more than 360 transactions in 2021 and issuing nearly $31 billion in financing commitments to middle market private ...
CHICAGO--(BUSINESS WIRE)--Antares today announced that it closed 139 transactions totaling almost $11 billion in financing commitments to middle market private equity-backed companies in the first ...
Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., ...
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial ...
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue ...
CHICAGO--(BUSINESS WIRE)--Antares today announced record 2021 performance supporting the growth and refinancing initiatives of new and existing borrowers within the healthcare and technology sectors.
¹ Denotes non-GAAP financial measure. Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies ...
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results